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ORIGINAL ARTICLE
Hepatitis E virus: Western Cape, South Africa
Prospective study
Richie G Madden, Sebastian Wallace, Mark Sonderup, Stephen Korsman, Tawanda Chivese, Bronwyn Gavine, 
Aniefiok Edem, Roxy Govender, Nathan English, Christy Kaiyamo, Odelia Lutchman, Annemiek A van der Eijk, 
Suzan D Pas, Glynn W Webb, Joanne Palmer, Elizabeth Goddard, Sean Wasserman, Harry R Dalton, C Wendy 
Spearman
Abstract
AIM
To conduct a prospective assessment of anti-hepatitis 
E virus (HEV) IgG seroprevalence in the Western Cape 
Province of South Africa in conjunction with evaluating 
risk factors for exposure.
METHODS
Consenting participants attending clinics and wards of 
Groote Schuur, Red Cross Children’s Hospital and their 
affiliated teaching hospitals in Cape Town, South Africa, 
were sampled. Healthy adults attending blood donor 
clinics were also recruited. Patients with known liver 
disease were excluded and all major ethnic/race groups 
were included to broadly represent local demographics. 
Relevant demographic data was captured at the 
time of sampling using an interviewer-administered 
confidential questionnaire. Human immunodeficiency 
virus (HIV) status was self-disclosed. HEV IgG testing 
was performed using the Wantai® assay.
RESULTS
HEV is endemic in the region with a seroprevalence of 
27.9% (n  = 324/1161) 95%CI: 25.3%-30.5% (21.9% 
when age-adjusted) with no significant differences 
between ethnic groups or HIV status. Seroprevalence in 
children is low but rapidly increases in early adulthood. 
With univariate analysis, age ≥ 30 years old, pork 
and bacon/ham consumption suggested risk. In the 
multivariate analysis, the highest risk factor for HEV 
IgG seropositivity (OR = 7.679, 95%CI: 5.38-10.96, 
P < 0.001) was being 30 years or older followed by 
pork consumption (OR = 2.052, 95%CI: 1.39-3.03, P  
< 0.001). A recent clinical case demonstrates that HEV 
genotype 3 may be currently circulating in the Western 
Cape.
CONCLUSION
Hepatitis E seroprevalence was considerably higher 
than previously thought suggesting that hepatitis 
E warrants consideration in any patient presenting 
with an unexplained hepatitis in the Western Cape, 
irrespective of travel history, age or ethnicity.
Key words: Hepatitis E; Seroprevalence; South Africa; 
Pork consumption; Genotype
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This is a prospective seroprevalence study of 
1161 participants assessing anti-hepatitis E virus (HEV) 
IgG seroprevalence in the Western Cape Province of 
South Africa. The only risk factors for seropositivity are 
pork consumption and individuals over 30 years of age. 
A recent clinical case suggests HEV genotype 3 may be 
circulating in South Africa.
Madden RG, Wallace S, Sonderup M, Korsman S, Chivese 
T, Gavine B, Edem A, Govender R, English N, Kaiyamo C, 
Lutchman O, van der Eijk AA, Pas SD, Webb GW, Palmer J, 
Goddard E, Wasserman S, Dalton HR, Spearman CW. Hepatitis 
E virus: Western Cape, South Africa. World J Gastroenterol 
2016; 22(44): 9853-9859  Available from: URL: http://www.
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INTRODUCTION
Globally, hepatitis E virus (HEV) is the most frequent 
aetiological cause of acute hepatitis[1]. It causes spo-
radic and epidemic infections, predominantly in young 
adults living in developing countries. In these regions, 
it is associated with HEV genotypes 1 and 2, which are 
obligate human pathogens and spread oro-faecally 
through infected water. Most patients experience a 
self-limiting hepatitis, except in pregnant women and 
patients with chronic liver disease, where mortality 
may reach 25% and 75% respectively[2].
In the developed world, hepatitis E is largely a 
porcine zoonosis caused by genotypes 3 and 4 and 
is a cause of self-limiting hepatitis in middle-aged 
and elderly men[2-4]. Chronic infection occurs in those 
who are immunosuppressed, including transplant 
recipients[5], patients with haematological malignancy 
and individuals with human immunodeficiency virus 
(HIV)[6]. An important route of infection is through con-
sumption of infected pig meat products in the human 
food chain[2].
Hepatitis E, invariably genotypes 1 and 2, is seen 
in a number of African countries. There have been 
several outbreaks observed in sub-Saharan African 
refugee camps, including recently South Sudan 
and Uganda[7,8]. In the 1980’s a large outbreak was 
reported in Namibia where HEV genotype 2 is known 
to circulate[9]. In South Africa, very few data regard-
ing HEV exists. Two seroprevalence studies from the 
1990’s demonstrated low rates but these studies were 
potentially limited as the screening tests employed are 
now known to have had poor sensitivity[10]. In addition, 
very few cases of hepatitis E from South Africa have 
been reported in the literature but recently, two cases 
caused by HEV genotype 3 have been described[11,12].
Given the paucity of data, we elected to prospec-
tively investigate the seroprevalence of anti-HEV IgG 
in a South African population in the Western Cape 
using a sensitive assay as well as assessing risk factors 
for anti-HEV IgG seropositivity. Unexpectedly, a case 
of acute hepatitis E infection was documented and is 
reported here. 
MATERIALS AND METHODS
HEV seroprevalence and risk factors
The study was designed to cover all age groups in 
addition to reflecting the population of the Western 
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Cape in terms of ethnic distribution. Participants were 
asked to self-identify their ethnicity and were randomly 
recruited and sampled from the three major ethnic 
groups aged 0 to > 60 years old from both a hospital 
and non-hospital setting. Participants were recruited 
from the general medical and Emergency Unit inpa-
tients and outpatients of Groote Schuur, Red Cross 
Childrens, New Somerset and UCT Private Academic 
Hospitals between 28/02/14-12/02/2015. Further-
more, healthy blood donors, prior to screening, from 
two blood donation centres in Cape Town, South Africa 
were included. Participants with known or reported 
liver disease were excluded. Following informed con-
sent, blood samples were drawn and each participant 
completed a structured questionnaire for demographic 
and known risk factors for hepatitis E acquisition, these 
included, consumption of pork, sausage, bacon/ham, 
fish and shellfish; type of dwelling (formal dwelling or 
informal dwelling/shack in back yard, informal dwell-
ing/shack not in back yard, other); access to piped 
water (piped water inside dwelling, piped water inside 
yard, piped water outside yard, no access to piped 
water); proximity to coast (coastal, < 5 km, 5-10 
km, > 10 km) and refuse disposal (removed by local 
authority/private company, communal refuse dump, 
own refuse dump, no rubbish disposal/other). Given 
the massive upscaling of HIV testing in South Africa, 
participants were asked to self-disclose their HIV sta-
tus, if known. Blood samples were stored at -70 ℃ and 
tested in batches for HEV anti-IgG using the Wantai® 
assay (Beijing, China) according to the manufacturer’s 
instructions.
Statistical analysis
Age-standardized seroprevalence was calculated using 
the 2014 South Africa Mid-Year population estimates 
as the reference population[13]. Age-specific percent-
ages were applied to the South African population, 
and then summed to determine the age-standardized 
seroprevalence for anti-HEV IgG in the population as a 
whole as well as between different ethnic groups. Con-
tinuous variables are described using counts and per-
centages and independent risk factors were explored 
by uni-variate binary logistic regression. Factors, which 
were found to be statistically significant on uni-variate 
analysis, were then modelled with multi-variate binary 
logistic regression using maximum-likelihood estima-
tion with parameters (0, 1), analysed with IBM SPSS 
V22.0. Statistical significance was accepted if p < 0.05.
Clinical case
A documented case of acute hepatitis E presenting to 
New Somerset hospital is described; the clinical course 
and laboratory findings are recorded. 
Ethics
Ethics approval was granted by the Faculty of Health 
Sciences Human Research Ethics Committee of the 
University of Cape Town. Patients ≥ 18 years provided 
consent whilst parents/guardians provided permis-
sion/consent for minors. Adolescents provided assent. 
RESULTS
About 1161 participants were included in the study 
with the 3 major ethnic groups in the Western Cape 
viz. Black Africans (n = 392, 33.5%), Mixed Ancestry 
(n = 455, 38.9%) and Whites (n = 322, 27.5%), pro-
portionally sampled. The mean age of the population 
sampled was 36.4 years (SD 22.3) and 53.3% were 
male. Notably, Whites < 16 years and Black Africans > 
60 years of age were relatively under-represented due 
to low attendance at sampling locations (Table 1 and 
Figure 1).
The overall anti-HEV IgG seroprevalence was 
27.9% (n = 324/1161, 95%CI: 25.3-30.5) and the 
age adjusted seroprevalence was 21.9%. Seropreva-
lence in children (< 19 years old) was approximately 
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Table 1  Data (%) for total population overall and age group seroprevalence and 95%CI in 3 racial groups in Western Cape, South 
Africa
Overall seroprevalence was 27.9% and age adjusted seroprevalence was 21.9%. 1Numbers too small to calculate a meaningful confidence interval. HEV: 
Hepatitis E virus.
Age
Group
(yr)
Total population (n  = 1161) Black African population (n  = 389) MA/Coloured population (n  = 452) White population (n  = 320)
IgG (n) HEV Seroprevalence %
(95%CI)
IgG (n) HEV Seroprevalence %
(95%CI)
IgG (n) HEV Seroprevalence % 
(95%CI)
IgG (n) HEV Seroprevalence % 
(95%CI)
0-4   6/72 8.3 (3.9-17.0)   2/36   5.6 (1.5-18.1)   4/31 12.9 (5.1-28.9) 0/51 0 (0-43.4)
5-9   6/78 7.7 (3.6-15.8)   1/26   3.8 (0.7-18.9)   5/45 11.1 (4.8-23.5) 0/71 0 (0-35.4)
10-14   7/72 9.7 (4.8-18.7)   3/27 11.1 (3.9-28.1)   4/42   9.5 (3.8-22.1) 0/31 0 (0-56.2)
15-19   8/95 8.4 (4.3-15.7)   4/23 17.4 (7.0-37.1)   4/42   9.5 (3.8-22.1)   0/301 0 (0-11.4)
20-29   17/179 9.5 (6.0-14.7)   2/62   3.2 (0.9-11.0)   9/54 16.7 (9.0-28.7) 6/63 9.5 (4.4-19.3)
30-39   42/142 29.6 (22.7-37.5) 14/52   26.9 (16.8-40.3) 17/45   37.8 (25.1-52.4) 11/45 24.4 (14.2-38.7)
40-49   67/153 43.8 (36.2-51.7) 22/62   35.5 (24.7-47.9) 22/49   44.9 (31.9-58.7) 23/42 54.8 (39.9-68.8)
50-59   62/126 49.2 (40.6-57.8) 15/36   41.7 (27.1-57.8) 26/47   55.3 (41.2-68.6) 21/43 48.8 (34.6-63.2)
60-69   67/152 44.1 (36.4-52.0) 24/43   55.8 (41.1-69.6) 19/58   32.8 (22.1-45.6) 24/51 47.1 (34.1-60.5)
70-79 34/68 50.0 (38.4-61.6)  6/17   35.3 (17.3-58.7) 16/29   55.2 (37.5-71.6) 12/22 54.5 (34.7-73.1)
80+   8/24 33.3 (18.0-53.3) 1/5 20.0 (3.6-62.4)   2/10 20.0 (5.7-51.0) 5/9 55.6 (26.7-81.1)
Total   324/1161 27.9 (25.3-30.5)   94/389   24.2 (20.2-28.7) 128/452   28.3 (24.4-32.6) 102/320 31.9 (27.0-37.2)
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Table 2  Risk factor analysis
10% with a rapid increase in seroprevalence in indi-
viduals older than 20 years of age (Figure 1). Various 
demographic and environmental factors were explored 
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with univariate analysis, age, ethnicity, gender, HIV 
status, consumption of pork, sausages, bacon/ham, 
fish, shellfish, type of dwelling, access to water, 
proximity to the coast and method of refuse disposal 
(Table 2). Age group ≥ 30 years (p < 0.001), pork 
consumption (p < 0.001) and bacon/ham consumption 
(p = 0.004) were strongly associated with a positive 
HEV IgG. However as the pork and bacon/ham are not 
independent from one another, only pork consumption 
was used in the multivariate analysis along with age 
group (< 30 years, ≥ 30 years). 
The model was statistically significant (p < 0.001) 
and therefore was able to determine the risk factors of 
people presenting with HEV IgG positive compared to 
those that were not and explained between 15%-22% 
of the variance . With pork in their diet, an individual 
had an increased risk (OR = 2.02, 95%CI: 1.5-2.73) 
of being HEV IgG positive compared to those who did 
not have pork in their diet. Individuals 30 years old 
or over had an increased risk (OR = 7.679, 95%CI: 
5.38-10.96, p < 0.001) of being HEV IgG positive 
compared to those under 30 years old. No other 
Potential risk factors (n  = 131) Univariate analyses
Groups n  (IgG%) P value OR (95%CI)
Race (n = 161) Black African (n = 389)   94 (24.2%) 0.073 -
MA/Coloured (n = 452) 128 (28.3%)   1.24 (0.91-1.69)
White (n = 320) 102 (31.9%)   1.47 (1.06-2.04)
Gender (n = 161) Male (n = 541) 161 (29.8%) 0.189 -
Female (n = 620) 163 (26.3%) 0.842 (0.65-1.09)
Pork (n = 131) Yes (n = 690) 228 (33.0%) < 0.001   1.93 (1.45-2.55)
No (n = 441)   90 (20.4%) -
Sausage  (n = 131) Yes (n = 853) 248 (29.1%) 0.210   1.22 (0.90-1.66)
No (n = 278)   70 (25.2%) -
Bacon/Ham (n = 131) Yes (n = 707) 220 (31.1%) 0.004   1.50 (1.14-1.98)
No (n = 424)   98 (23.1%) -
Fish (n = 131) Yes (n = 1055) 299 (28.3%) 0.532   1.19 (0.69-2.03)
No (n = 76)   19 (25.0%)
Shellfish (n = 131) Yes (n = 548) 163 (29.7%) 0.238   1.17 (0.90-1.52)
No (n = 583) 155 (26.6%) -
Type of dwelling (n = 161) Formal Dwelling (n = 1050) 296 (28.2%) 0.642 -
Shack in Yard (n = 88)   21 (24.0%)   0.80 (0.48-1.40)
Shack not in Yard (n = 19)     5 (26.3%)   0.91 (0.33-2.55)
Other (n = 4)     2 (50.0%)     2.55 (0.36-18.17)
Water access (n = 1161) Piped dwelling (n = 1041) 292 (28.0%) 0.516 -
Piped yard (n = 68)   17 (25.0%)  0.855 (0.49-1.51)
Community tap (n = 44)   11 (25.0%)  0.855 (0.43-1.71)
No water access (n = 8)     4 (50.0%)    2.565 (0.64-10.32)
Proximity to coast (n = 1160) Coastal (n = 114)   32 (28.0%) 0.935 -
Under 5 km (n = 209)   62 (29.7%) 1.081 (0.65-1.79)
5-10 km (n = 313)   85 (27.2%) 0.955 (0.59-1.54)
Over 10 km (n = 524) 145 (27.7%) 0.980 (0.62-1.54)
Refuse disposal (n = 1160) Local authority (n = 1124) 315 (28.0%) 0.725 -
Communal dump (n = 20)     5 (25.0%) 0.856 (0.31-2.40)
Own dump (n = 8)     3 (37.5%) 1.541 (0.37-6.50)
No rubbish disposal (n = 8)     1 (12.5%) 0.367 (0.05-3.00)
HIV status (n = 891) Positive (n = 60)   14 (23.3%) 0.340   1.35 (0.73-2.50)
Negative (n = 831) 242 (29.1%) -
Age group (n = 1156) < 30 yr (n = 496) 44 (8.9%) < 0.001 -
≥ 30 yr (n = 660) 280 (42.4%)   7.569 (5.36-10.70)
Multivariate analysis (n = 1126)
Pork Yes (n = 686) 228 (33.2%) < 0.001   7.679 (5.38-10.96)
Age group ≥ 30 yr (n = 660) 276 (42.3%) < 0.001 2.021 (1.50-2.73)
Total sample
Black african
Ma/coloured
White
Seroprevalence
Age adjusted
seroprevalence
60.0
50.0
40.0
30.0
20.0
10.0
0.0
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Figure 1  Overall seroprevalence curve and individual seroprevalence 
curves in 3 racial groups in Western Cape, South Africa. Anti-HEV IgG 
seroprevalence by age in Western Cape, South Africa. 
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risk factors were associated with HEV seropositivity 
(Table 2) and therefore excluded from the multivariate 
analysis.
Clinical case of hepatitis E
In January 2014, a 54-year-old white male presented 
to New Somerset Hospital, Cape Town, with acute liver 
failure secondary to a severe hepatitis. Initial clinical 
examination revealed marked icterus, mild abdominal 
ascites and smooth non-tender hepatomegaly, as well 
as signs of chronic liver disease including palmar ery-
thema and spider telangiectasia on the chest wall. The 
patient worked as a truck driver but had no history of 
recent travel (in the last 3 mo prior to presentation) 
outside of the Western Cape. He was not known to 
have any medical co-morbidities but reportedly con-
sumed significant alcohol. At presentation, blood tests 
demonstrated (normal range in parentheses): Bilirubin 
407 μmol/L (0-18 μmol/L), albumin 28 g/L (35-52 g/L), 
alanine aminotransferase (ALT) 3054 IU/L (0-40 IU/L), 
prothrombin time-International normalized ratio (PT-
INR) 2.74. Serology for hepatitis A, B, C and HIV were 
negative. Despite maximal supportive care he demised 
on day 3 following admission as a result of fulminant 
hepatic failure. On the day of his death, hepatitis E 
IgM test returned positive and subsequently HEV RNA 
genotype 3e was confirmed by polymerase chain reac-
tion (PCR) (see Figure 2). 
DISCUSSION
The seroprevalence in Western Cape is much higher 
than has been previously described in South African 
populations[10,14]. We found that the overall seropreva-
lence was 27.9% (21.9% when age-adjusted) and 
was similar between genders, ethnic groups and HIV 
status. The age-related seroprevalence curve shows 
that HEV IgG seropositivity increases with age, but 
in a non-linear fashion. Seroprevalence is very low in 
children and young adults, rapidly increasing between 
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Figure 2  A maximum likelihood tree constructed in MEGA6 from an alignment of a 301nt fragment of ORF2. Bootstrap support above 60% is shown. Our 
patient’s viral sequence, GenBank accession KT833800, is highlighted in red. The tree is rooted on the HEV reference sequence (genotype 1). Sequences for 
comparison have names starting with genotype, followed by Genbank accession number, followed by country ISO 3166-1 abbreviation (CA: Canada; ES: Spain; GB: 
United Kingdom; JP: Japan; NL: The Netherlands; TW: Taiwan; US: United States of America; ZA: South Africa), and ending in source (D: Deer; H: Human; P: Pig). 
The patient’s viral sequence clusters within genotype 3 (with subgenotype 3e), in keeping with other viruses recently described in South Africa[11,12,24].
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the ages of 20 and 30 years and then plateaus off. 
Multivariate risk factor analysis demonstarted that the 
only other significant association with anti-HEV IgG 
seropositivity was the consumption of pork. 
Two previous studies from South Africa in the 
1990’s described seroprevalence rates of 10.7% and 
1.8%-2.6%, respectively. The overall seroprevalence 
in the current study was an order of magnitude higher. 
The reason for this difference could relate to geograph-
ical location, as both the above previous studies were 
performed in different areas of South Africa and it is 
known that HEV seroprevalence can vary enormously 
between regional areas within countries[15]. Another 
possible explanation is that there has been an increase 
in the exposure rates of hepatitis E in South Africa 
over the last 20 years, which may include changes 
in migration, diet and enzootic disease. However, the 
likely dominant explanation relates to the sensitivity of 
the IgG assays employed in the previous studies. The 
first generation of anti-HEV IgG assays used in studies 
in the 1990’s lacked sensitivity and generally reported 
spuriously low seroprevalence rates[16]. In contrast, the 
assay employed in our study has a sensitivity of 98% 
at detecting previous infection and produces much 
higher estimates of seroprevalence[17,18]. However, 
in common with all currently available anti-HEV IgG 
assays, the specificity of the Wantai® assay for detect-
ing previous infection has not been fully established 
although indirect evidence suggests that it has an 
acceptable specificity. This includes very low serop-
revalence rates in young children (in the current study 
and others from Nepal, Bangladesh and France)[19] and 
adult populations (Fiji 2%[20], New Zealand 4%[21] and 
Scotland 4.6%[22])[19-21]. Hence, the high seropreva-
lence rate reported in our study is probably due to the 
high sensitivity of the assay used.
The shape of the anti-HEV seroprevalence curve 
in Western Cape (low rates in childhood, with a rapid 
increase in early adulthood) is similar to that seen in 
hyperendemic developing countries such as Nepal and 
Bangladesh, where HEV genotype 1 predominates[18]. 
However, the risk factor analysis showed that only pork 
consumption was significantly associated with HEV 
seropositivity which is typical of European populations 
with high incidences of locally-acquired porcine HEV 
genotype 3[3,15,23]. This finding contrasts with previ-
ous data from a different area of South Africa, which 
showed that rural mud hut dwellers with no access 
to clean water had higher seropositivity[13]. Moreover, 
there have been no outbreaks of hepatitis E reported 
in South Africa which would also argue against 
genotype 1 possibly being the dominant circulating 
genotype. Our clinical case, in addition to others, sug-
gests that HEV genotype 3 may be currently circulating 
in Western Cape. The other cases include two of HEV 
genotype 3 infection in immunosuppressed patients 
documented in Cape Town[11,12].
The strengths of the current study are that a highly 
sensitive, partially validated assay was employed to 
estimate seroprevalence and that the study population 
comprised of large numbers of individuals, including 
adults and children, from all racial groups. The main 
limitation of the study is that the population was a 
heterogeneous “convenience population” comprising 
hospital in-patients, outpatients and healthy blood 
donors and may not be representative of the popula-
tion of Western Cape as a whole. The population 
studied may have over or under-represented certain 
population subgroups. This includes white children and 
elderly black South Africans, very few of whom were 
included in the study.
In conclusion, HEV is endemic in the Western Cape, 
South Africa with seroprevalence of 27.9%. Seropreva-
lence in children is very low with a rapid increase in 
early adulthood. The only risk factors for seropositivity 
are pork consumption and individuals over 30 years 
of age. Recent cases suggest HEV genotype 3 may 
be currently circulating in South Africa. The diagnosis 
of hepatitis E should be considered in any patient 
presenting with hepatitis in Western Cape, irrespective 
of travel history, age or ethnicity.
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